Magnetically-assisted viral transduction (magnetofection) medical applications: An update.

Gene therapy involves replacing a faulty gene or adding a new gene inside the body's cells to cure disease or improve the body's ability to fight disease. Its popularity is evident from emerging concepts such as CRISPR-based genome editing and epigenetic studies and has been moved to a clinical setting. The strategy for therapeutic gene design includes; suppressing the expression of pathogenic genes, enhancing necessary protein production, and stimulating the immune system, which can be incorporated into both viral and non-viral gene vectors. Although non-viral gene delivery provides a safer platform, it suffers from an inefficient rate of gene transfection, which means a few genes could be successfully transfected and expressed within the cells. Incorporating nucleic acids into the viruses and using these viral vectors to infect cells increases gene transfection efficiency. Consequently, more cells will respond, more genes will be expressed, and sustained and successful gene therapy can be achieved. Combining nanoparticles (NPs) and nucleic acids protects genetic materials from enzymatic degradation. Furthermore, the vectors can be transferred faster, facilitating cell attachment and cellular uptake. Magnetically assisted viral transduction (magnetofection) enhances gene therapy efficiency by mixing magnetic nanoparticles (MNPs) with gene vectors and exerting a magnetic field to guide a significant number of vectors directly onto the cells. This research critically reviews the MNPs and the physiochemical properties needed to assemble an appropriate magnetic viral vector, discussing cellular hurdles and attitudes toward overcoming these barriers to reach clinical gene therapy perspectives. We focus on the studies conducted on the various applications of magnetic viral vectors in cancer therapies, regenerative medicine, tissue engineering, cell sorting, and virus isolation.

Covalently-Bonded Coating of L-Arginine Modified Magnetic Nanoparticles with Dextran Using Co-Precipitation Method.

In this study, L-arginine (Arg) modified magnetite (Fe3O4) nanoparticles (RMNPs) were firstly synthesized through a one-step co-precipitation method, and then these aminated nanoparticles (NPs) were, again, coated by pre-oxidized dextran (Dext), in which aldehyde groups (DextCHO) have been introduced on the polymer chain successfully via a strong chemical linkage. Arg, an amino acid, acts as a mediator to link the Dext to a magnetic core. The as-synthesized Arg-modified and Dext-coated arginine modified Fe3O4 NPs were characterized by scanning electron microscopy (SEM), X-ray diffraction (XRD), Fourier transformation infrared spectroscopy (FT-IR), thermogravimetric analysis (TGA), and vibrating sample magnetometer (VSM). Both synthesized samples, XRD pattern and FT-IR spectra proved that the core is magnetite. FT-IR confirmed that the chemical bonds of Arg and Dext both exist in the samples. SEM images showed that the NPs are spherical and have an acceptable distribution size, and the VSM analysis indicated the superparamagnetic behavior of samples. The saturation magnetization was decreased after Dext coating, which confirms successive coating RMNPs with Text. In addition, the TGA analysis demonstrated that the prepared magnetic nanocomposites underwent various weight loss levels, which admitted the modification of magnetic cores with Arg and further coating with Dext.